Kaplan Fox Encourages Corcept Therapeutics, Inc. (CORT) Investors to Inquire About Ongoing Investigation

On February 24, 2026, Kaplan Fox & Kilsheimer LLP announced an investigation into potential securities violations involving Corcept Therapeutics, Inc. (NASDAQ: CORT). This inquiry follows significant declines in Corcept's stock price after concerning news regarding its drug relacorilant, aimed at treating hypertension secondary to hypercortisolism. On December 31, 2025, Corcept revealed that the U.S. Food and Drug Administration (FDA) had issued a Complete Response Letter (CRL) for its New Drug Application. The FDA's letter indicated that additional evidence of effectiveness was necessary before a favorable benefit-risk assessment could be made.

Subsequently, upon news of the CRL, Corcept’s stock plummeted from $70.20 per share to $34.80—over a 50% decline. Further complicating matters, a corrected version of the CRL was disseminated on January 30, 2026, revealing that the FDA had previously expressed concerns about the adequacy of Corcept’s clinical development program and warned of potential review issues. This led to another sharp decline in the stock price, falling more than 12% during intraday trading.

Kaplan Fox is reaching out to investors who may have suffered losses or possess information pertinent to the investigation. With over 50 years of experience in securities litigation, Kaplan Fox aims to uphold investor rights and address alleged violations effectively.

Investors affected by the recent events involving Corcept are encouraged to contact Kaplan Fox to explore their options. For inquiries, individuals can reach Jeffrey P. Campisi or Laurence D. King via telephone or email, as detailed in the press release.

The recent turmoil surrounding Corcept Therapeutics, Inc. (CORT) following the FDA's issuance of a Complete Response Letter (CRL) has raised significant concern among investors. The initial announcement on December 31, 2025, resulted in a staggering 50% decline in share price, plunging from $70.20 to $34.80. This underscores the market's sensitivity to regulatory feedback, especially regarding new drug applications.

The subsequent dissemination of additional information about the CRL on January 30, 2026, which highlighted the FDA's longstanding concerns regarding Corcept's clinical development program, led to further declines, with shares dropping over 12% in intraday trading. This pattern of volatility suggests that investor sentiment is heavily influenced by regulatory developments, reflecting broader concerns about the viability of potential treatments and the company's overall direction.

For current investors or those considering entering a position in Corcept, this may present a critical juncture. It is vital to conduct thorough due diligence, specifically focusing on:

1. **Regulatory Updates**: Monitor further communication from the FDA. The company's ability to address the FDA's concerns will play a pivotal role in the stock's recovery.

2. **Legal Developments**: The ongoing investigation led by Kaplan Fox raises the possibility of potential securities violations. Investors should consider the implications of this investigation on stock valuation and corporate governance.

3. **Long-Term Prospects**: Assess the core pipeline of Corcept's products, beyond relacorilant. Diversifying product offerings can mitigate risks associated with individual drug approvals.

4. **Market Sentiment**: Keep abreast of analyst ratings and market commentary. As data emerges and the company navigates regulatory challenges, sentiment can shift, presenting investment opportunities or risks.

In conclusion, while volatility may present short-term trading opportunities, investors should weigh the potential for long-term value against regulatory and legal uncertainties. Caution and strategic positioning will be key as this situation unfolds.